Companies · Pharmaceuticals

ResBiotic Nutrition, Inc.

BIRMINGHAM · Pharmaceuticals

Diligence memoA one-page analyst read on ResBiotic Nutrition, Inc. — recommendation, valuation, rhythm, risks.
$6.6M
Total raised · real
3
Rounds
0.6×
Latest step-up
Top 54%
Sector rank · raised
Seed
Latest stage · inferred · Fri Feb 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

ResBiotic Nutrition, Inc. looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.39× the median modeled value of Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era.
  • Within the normal band (139% of peer median) for its niche.
Quiet
  • Last raise 16 mo ago; this sector typically re-raises about every 13 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

ResBiotic Nutrition, Inc. is one of 1613 Pharmaceuticals companies tracked from BIRMINGHAM. By capital raised it ranks mid-pack (ahead of 47% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2021
Year incorporated
2025-02-21
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MSeed · 2021-10-01 Raised $1.5M (real) Modeled valuation $30M (est)$1.5M$30MSeed2021Seed · 2024-01-30 Raised $2.6M (real) Modeled valuation $16M (est)$2.6M$16MSeed2024Seed · 2025-02-21 Raised $2.5M (real) Modeled valuation $8.5M (est)$2.5M$8.5MSeed2025Seed · 2025-02-21 Raised $1.5M (real) Modeled valuation $5.1M (est)$1.5M$5.1MSeed2025+$2.6M+$2.5M+$1.5MCumulative $8.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.5M · 2021
Seed extension$2.6M · 2024
Seed extension$2.5M · 2025
Seed extension$1.5M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$8.5M
Base estimate est.
$1.9M
Conservative case
$19.0M
Upside case
$12.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $29.8M · 2021-10-012021Seed · modeled $15.6M · 2024-01-30Seed · modeled $8.5M · 2025-02-21Seed · modeled $5.1M · 2025-02-212025
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
1.4 yr
Elapsed time used
1.4 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
14 mo
Avg between rounds
$2.0M/yr
Capital velocity
4.8 yr
On record since
2021
First round
4
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.8× of median
This company$6.6M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.9× of median
This company$1.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$8.5M
Sector median$76.1M

Raised more than 47% of sector peers (real $). Modeled value above 15% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #3 of 19.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0MCapital raised (log)Kairos Pharma, LTD. · Seed Raised $4.2M · modeled $12.5M (est)Branch Therapeutics, Inc. · Seed Raised $4.0M · modeled $12.4M (est)Califia Pharma, Inc. · Seed Raised $4.4M · modeled $8.5M (est)BTB Therapeutics, Inc. · Seed Raised $6.7M · modeled $7.9M (est)Avana Health, Inc. · Seed Raised $3.0M · modeled $6.9M (est)Aptevo Therapeutics Inc. · Seed Raised $2.1M · modeled $6.7M (est)Owp Pharmaceuticals, Inc. · Seed Raised $5.1M · modeled $6.6M (est)Xtresse, Llc · Seed Raised $2.7M · modeled $6.5M (est)Lumina Pharmaceuticals Inc. · Seed Raised $2.0M · modeled $6.1M (est)Pneuma Respiratory, Inc. · Seed Raised $3.6M · modeled $6.0M (est)Sea Pharmaceuticals, LLC · Seed Raised $6.5M · modeled $5.3M (est)ResBiotic Nutrition, Inc. (this company) Raised $6.6M · modeled $8.5M (est)ResBiotic Nutrition, Inc.
CompanyStageRaised · realValue · estvs peer med.
Kairos Pharma, LTD.Seed$4.2M$12.5M2.05×
Branch Therapeutics, Inc.Seed$4.0M$12.4M2.02×
ResBiotic Nutrition, Inc. this companySeed$6.6M$8.5M1.39×
Califia Pharma, Inc.Seed$4.4M$8.5M1.38×
BTB Therapeutics, Inc.Seed$6.7M$7.9M1.30×
Avana Health, Inc.Seed$3.0M$6.9M1.13×
Aptevo Therapeutics Inc.Seed$2.1M$6.7M1.10×
Owp Pharmaceuticals, Inc.Seed$5.1M$6.6M1.07×
Xtresse, LlcSeed$2.7M$6.5M1.06×
Lumina Pharmaceuticals Inc.Seed$2.0M$6.1M1.00×
Pneuma Respiratory, Inc.Seed$3.6M$6.0M0.98×
Sea Pharmaceuticals, LLCSeed$6.5M$5.3M0.86×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.5M2021-10-01$7.5M$29.8M90%
Seed$2.6M2024-01-30$13.2M$15.6M90%
Seed$2.5M2025-02-21$12.5M$8.5M90%
Seed$1.5M2025-02-21$7.5M$5.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.5M2021-10-01
    • First recorded raise — entered as Seed.
    • 8 investors on this round.
  2. Seed$2.6M2024-01-30
    • Raised again after 28 mo — slower than the ~13 mo sector norm.
    • Round 1.8× larger than the prior — scaling up.
    • 6 investors on this round.
  3. Seed$2.5M2025-02-21
    • Raised 13 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  4. Seed$1.5M2025-02-21
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
2026 ~Q2
Modeled next raise · ~14mo cadence
$1.5M
Modeled next size est.range $1.5M$2.4M
0.6×
Last step-up
$2.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Braxton Vivek Goodrich1 other2021-10
Charitharth Vivek Lal1 other2021-10
Micheal Vivek Bush2025-02
Sanjay Vivek Singh2024-01
Registry & provenance

ResBiotic Nutrition, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1888891
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
ResBiotic, Inc.PharmaceuticalsSeed$1.6M$43.0Mnetwork2 shared operators · same sector · same stage
NanoPharmaceuticals LLCPharmaceuticalsSeed$6.6M$2.2Msame sector · same stage
BTB Therapeutics, Inc.PharmaceuticalsSeed$6.7M$7.9Msame sector · same stage
Sea Pharmaceuticals, LLCPharmaceuticalsSeed$6.5M$5.3Msame sector · same stage
CoLabs Int'l, Corp.PharmaceuticalsSeed$6.4M$3.1Msame sector · same stage
Whistler Medical Marijuana CorpPharmaceuticalsSeed$6.4M$5.1Msame sector · same stage
Amytrx Therapeutics, Inc.PharmaceuticalsSeed$7.0M$4.6Msame sector · same stage
Urigen Pharmaceuticals, Inc.PharmaceuticalsSeed$7.1M$6.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
ResBiotic, Inc.PharmaceuticalsSeed$43.0M97%
Microbion CorpPharmaceuticalsSeries B$329.0M84%
Resq Pharmaceuticals Inc.PharmaceuticalsSeries A$178.0M84%
RxBio Holdings, Inc.PharmaceuticalsSeries D+$12.0M82%
Vireo Health, Inc.PharmaceuticalsSeries B$547.2M82%
Return Health Inc.PharmaceuticalsPre-Seed$3.1M81%
LSK BioPartners, Inc.PharmaceuticalsSeries B$680.1M81%
Retension Pharmaceuticals, Inc.PharmaceuticalsSeries A$44.1M80%
Frequently asked
How much funding has ResBiotic Nutrition, Inc. raised?
ResBiotic Nutrition, Inc. has raised approximately $6.6M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is ResBiotic Nutrition, Inc.'s estimated valuation?
Provath's modeled valuation for ResBiotic Nutrition, Inc. is approximately $8.5M (modeled range $1.9M–$19.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ResBiotic Nutrition, Inc. at?
ResBiotic Nutrition, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Feb 21.
What does ResBiotic Nutrition, Inc. do and where is it based?
ResBiotic Nutrition, Inc. operates in the Pharmaceuticals sector, based in BIRMINGHAM.
Explore related

See where ResBiotic Nutrition, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ResBiotic Nutrition, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.